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Purpose: Few studies looking for an effective biomarker to predict delirium have been performed. This study was
designed to investigate whether a change in inﬂammatory status, indicated by blood natural killer (NK) cell
activity, predicts delirium.
Methods: This prospective study, performed in 4 university and 1 general hospital from September, 2011 to
October, 2012, included 29 patients. Eligible patients were 65–89 years old, newly and emergently admitted.
Patients were assessed daily, up to 7 days, for occurrence of DSM-IV-deﬁned delirium. The main outcome
measure was change in blood NK cell activity between the ﬁrst and second mornings after admission.
Results: The mean change in blood NK cell activity on the second morning, compared to the ﬁrst morning, in
patients developing delirium (n = 9) was signiﬁcantly greater than that in patients without delirium (n = 20)
(6.0% [SD 8.4] vs. −1.4% [9.0], respectively, t = 2.10, P = 0.045). Signiﬁcant difference between the groups
was still found after adjusting for age, the history of previous delirium, and the Clinical Dementia Rating score
(F = 6.63, P = 0.017). Of note is that 8 of 9 (89%) patients developing deliriumhad increased bloodNK cell activity,
as did only 8 of 20 (40%) patients without delirium, giving measurement of this parameter, for distinguishing the
two groups, a sensitivity of 89%, speciﬁcity 60%, positive predictive value 50%, negative predictive value 92%, positive
likelihood ratio 2.22, and negative likelihood ratio 0.19. When combining this predictor with another predictor, a
Delirium Rating Scale-Revised-98 severity score of 5 or more at baseline, positive and negative likelihood ratios
were 7.80 and 0.24, respectively.
Conclusion: Increase in blood NK cell activity may be associatedwith developing delirium. Further studies including
larger numbers of patients are needed to justify the preventive use of drugs for patients meeting criteria for both
predictors.© 2013 The Authors. Published by Elsevier Inc. Open access under CC BY-NC-SA license.1. Introduction
Delirium is an acute change in cognition, with altered consciousness
and impaired attention, that ﬂuctuates over time (American Psychiatric-R98, the DeliriumRating Scale-
y, Juntendo University Nerima
Japan. Tel.: +81 3 5923-3111;
. Open access under CC BY-NC-SA licenAssociation, 2000). Reportedly, its prevalence ranges from 11% to 33%
on admission, and its incidence during the hospital stay ranges between
3% and 56% (Michaud et al., 2007). With an increasingly aging popula-
tion, delirium will increase further. Antipsychotics are widely used for
treatment, but the side-effects are a cause for concern. Therefore,
there is considerable interest regarding new approaches to the preven-
tion and management of delirium. Although it is challenging to formu-
late etiopathogenic models that integrate risk factors already identiﬁed,
it has been suggested that the neuroinﬂammatory pathway can be a
major process underlying delirium when the individual is exposed to
an acute systemic inﬂammatory condition, such as infection or after
surgery (Cerejeira et al., 2010). However, studies in humans in this
ﬁeld remain very scarce. Recently, blood levels of interleukin (IL)-6
and IL-8 or the β subunit of the S100 proteinwere reported to be higherse.
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Munster et al., 2008, 2010). Froma predictive point of view, a biomarker
that changes prior to the onset of delirium is required. So far, three of
the ﬁve studies of insulin-like growth factor 1 (IGF-1) in delirium indi-
cate an association between IGF-1 and delirium occurrence (Adamis
and Meagher, 2011). We previously have reported increased IL-1β
and decreased natural killer (NK) cell activity with the progress of
agitation in patients with Alzheimer disease (Higuchi et al., 2010), and
now we have focused on these in the context of delirium prediction.
While Adamis et al. (2007) did not recognize a relationship between
deliriumand blood IL-6, IL-1β or TNF-α, as biologicalmarkers, in elderly
medical inpatients, the relationship between deliriumand bloodNK cell
activity has not been investigated sufﬁciently. Due to the swift response
of NK cells to inﬂammation, we hypothesized that a change in blood NK
cell activity may predict developing delirium.
2. Methods
Weexamined the patients included in theDELIRIA-J (Delirium Inter-
vention Research for Improving Acute phase outcomes in Japan) trial, in
which preventive effects of ramelteon on delirium were examined
(UMIN Clinical Trials Registry ID: UMIN000005591, URL www.umin.
ac.jp/ctr/index-j.htm) (Hatta et al., in press); For the purpose of current
study, patients assigned to receive placebo (n = 34)were included and
those assigned to receive ramelteon (n = 33) were not, as ramelteon
appeared to have preventive effects on delirium.
2.1. Setting and participants
The study proceeded over a 14 month period (September 1, 2011 to
October 31, 2012) in 4 university hospitals and 1 general hospital. All
study protocols were approved by the institutional review board at
each site, and written informed consent was obtained from patients or
their substitute decision makers.
Eligible patients were 65–89 years old, newly admitted due to an
emergency, and able to take medicine orally. Patients were admitted
via emergency rooms to intensive care units or regular acute wards. At
the time of admission, they were consecutively screened. Patients
with delirium at the time of admission were not enrolled in the study.
Patients were approached for enrollment purposes before the ﬁrst
night of admission. Patients were excluded from the study if they had
an expected stay or life expectancy of less than 48 h.
The observation period was one week long, and we supposed that it
would be difﬁcult during that time to discriminate between delirium
and the cognitive ﬂuctuation of certain diseases, such as severe liver
dysfunction and Lewy Body disease. Therefore, such diseases were
excluded in advance. Lewy Body disease was excluded on the basis of
prior diagnosis.
Withdrawal syndromes of alcohol dependency and drug abuse can
include delirium, an etiology obviously different from delirium caused
by systemic diseases. Patients with psychotic disorders or bipolar disor-
ders are usually under treatment with antipsychotics, which may pre-
vent the development of delirium. Therefore, such patients were also
excluded.
During the study period, 1126 patients were assessed for eligibility,
and 1059 patients were excluded. Of the 697 patients admitted to inten-
sive care units, 658 were intubated or had a life expectancy of less than
48 h, and 306 out of 429 patients admitted to regular acute wards had
an expected stay of less than 48 h. Diagnoses of severe liver dysfunction,
Lewy Body disease, alcohol dependency, psychotic disorder, or bipolar
disorder accounted for exclusion of 61 patients. Thus, 1025 patients did
not meet inclusion criteria. In addition, 3 patients admitted to intensive
care units and 31 patients admitted to regular acute wards refused to
participate. Thus, 67 patients, consisting of 24 admitted to intensive
care units and 43 admitted to regular acute wards, were included in
the study. The 24 patients admitted to intensive care units stayed therefor at least the ﬁrst 3 days, during which blood samples were obtained.
Thereafter, 1 patient was transferred to a regular acute ward. The rate
of study participation among eligible patients was 66% (67/101). No pa-
tient withdrew consent. They were randomly assigned using the sealed
envelopemethod to receive ramelteon (8 mg/day; n = 33) and placebo
(n = 34). The number of patients discharged before day 7 was 13, but
there were no discharges within 48 h after admission.
As ramelteon has preventive effects on delirium (Hatta et al., in
press), only patients assigned to receive placebo (n = 34) were includ-
ed in the analysis. Delirium developed in 11 patients by day 7 from
admission, but not in the remaining 23 patients. Blood samples could
not be obtained in 2 patients who developed delirium on the ﬁrst
night. The timing of delirium occurrence in the remaining 9 patients
was as follows: the second night, 1 patient; the third night, 4 patients;
the fourth night, 1 patient; the ﬁfth night, 1 patient; the sixth night, 2
patients. Also, we failed to obtain blood samples in 3 patients without
delirium.
2.2. Assessment and measurement of blood indicators
Before starting the study, site-coordinators were trained as raters to
assess outcomes. All site-coordinators were experienced psychiatrists.
At the time of admission, baseline characteristics were collected. Also, re-
sults of the Acute Physiology and Chronic Health Evaluation (APACHE) II
(APACHE II) (Knaus et al., 1985), the Charlson Comorbidity Index
(Charlson et al., 1987), and the Eastern Cooperative Oncology Group Per-
formance Status (Falkson et al., 1980) were recorded to indicate physical
condition. The Clinical Dementia Rating (CDR) was used to evaluate the
existence and severity of dementia (Hughes et al., 1982). A family mem-
ber who knew the patient before admission was interviewed for the CDR
determination. The Delirium Rating Scale-Revised-98 (DRS-R98) was
used to measure delirium symptoms (Trzepacz et al., 2010). APACHE II,
Performance Status, and DRS-R98 were performed daily up to 7 days.
The DRS-R98 was measured between 10:00 and 11:00 AM. Once deliri-
um occurred, the etiology according to the Delirium Etiology Rating
Checklist was recorded (Trzepacz, 1999). Deliriumwas deﬁned according
to the Diagnostic and Statistical Manual of Mental Disorder, text revision,
4th ed (American Psychiatric Association, 2000). The same person that
diagnosed delirium using the DSM-IV-TR performed the rating scales
assessments.
Blood NK cell activity was measured on the ﬁrst and second morn-
ings after admission. As mentioned in the Introduction, we have previ-
ously reported changes in inﬂammatory markers prior to the onset of
agitation in patients with Alzheimer disease (Higuchi et al., 2010).
Therefore, we focused on these markers in the context of delirium
prediction, and presumed that values of the markers on the second
morning would have increased or decreased compared to those on the
ﬁrst morning after admission. Blood samples were obtained by cubital
puncture at 6:00 AM before breakfast. NK cell activity was measured
in a standard 4 h chromium (Cr) release assay, as previously described
(Nakamura et al., 2003). Production of IL-1β fromperipheralmonocytes
was assessed by a high sensitivity enzyme-linked immunosorbent assay
(ELISA), as described elsewhere (Baqui et al., 2000). Brieﬂy, after plasma
was separated by centrifugation, monocytes were isolated by Ficoll–
Hypaque gradient separation followed by overnight plastic adherence.
Cultured monocytes were stimulated with LPS of either P. gingivalis or
F. nucleatum for 2, 8, 24, and 48 h, and supernatant ﬂuidswere collected.
IL-1β levels in supernatant ﬂuids were determined by ELISA.
2.3. Data analysis
Weassumed that bloodNK cell activity or IL-1βwould increase in 50%
of patientswithout deliriumand 85% of patients developing delirium, and
that 25% of patientswould develop delirium. The statistical powerwas set
as power = 1-β = 80%, and sensitivity to α = 5% to be able to detect
differences in the effects of delirium. Power analysis consequently set
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patients developing delirium. Thus, 51 patients in total were required
for the study purpose. We closed study after 67 patients were enrolled
(the ramelteongroup,n = 33; the placebo group, n = 34), as 32patients
per group were required for the Deliria-J trial. In the present study, only
the placebo group (n = 34) was included, which is 67% (34/51) of the
required number of patients.
Data were collected on standardized forms and statistical analyses
were performed using SPSS version 20-J software (SPSS, Tokyo, Japan).
Differences between categorical variables in patient demographics and
clinical characteristics were calculated using Fisher's exact test. Differ-
ences between sequential variables were calculated using the unpaired
t test (with Welch correction if applicable). If data were not sampled
from Gaussian distributions, a non-parametric test (Mann–Whitney
test) was used. To control for the effect of age, the history of previous
delirium, and the CDR score on the change in NK cell activity or IL-1β,
one-way analysis of covariance was used. We examined the predictive
value of the DRS-R98 severity score at baseline for delirium. Cutoff scores
for the DRS-R98 severity scale at baseline were determined using
receiver-operator characteristic (ROC) analyses to determine theYouden
Indexwhen comparing patients developing deliriumwith patientswith-
out delirium. Sensitivity, speciﬁcity, positive predictive value, negative
predictive value, positive likelihood ratio (sensitivity/1-speciﬁcity), and
negative likelihood ratio (1-sensitivity/speciﬁcity) were also calculated.
All statistical tests were two-tailed. Values of P b 0.05 were regarded as
statistically signiﬁcant.3. Results
3.1. Baseline characteristics
Table 1 shows baseline characteristics. There were no signiﬁcant
differences in themean age, the rate of previous delirium, the rate of de-









Age, y 77.2 (6.5) 81.1 (7.5) 0.16
Male, % 6 (30%) 5 (56%) 0.24
Body mass index 21.6 (4.6) 20.9 (3.3) 0.70
Habitual drinking 2 (10%) 1 (11%) 1.00
Habitual sleeping pills 4 (20%) 1 (11%) 1.00
Opioid 0 0
Previous delirium 0 (0%) 1 (11%) 0.31
Dementia 3 (15%) 3 (33%) 0.34
Alzheimer's disease 2 (10%) 1 (11%) 1.00
Admission diagnosis
Stroke 3 (15%) 3 (33%) 0.34
Infection 5 (25%) 2 (22%) 1.00
Fracture 5 (25%) 1 (11%) 0.63
Heart failure/myocardial
infarction
1 (5%) 2 (22%) 0.22
Other 6 (30%) 1 (11%) 0.38
Number of medical or surgical
co-morbidities
1.1 (1.4) 1.1 (1.5) 0.98
Charlson Comorbidity Index 2.5 (2.6) 3.0 (1.7) 0.56
APACHE II 14.6 (2.6) 14.8 (2.6) 0.83
Performance Status 3.3 (0.9) 3.2 (1.0) 0.83
Clinical Dementia Rating 0.4 (0.8) 0.9 (1.0) 0.16
Delirium Rating Scale-Revised-98 3.6 (4.5) 7.4 (4.7) 0.044
Blood NK cell activity on the ﬁrst
morning, %
30.0 (11.2) 33.9 (18.8) 0.49
Blood IL-1β on the ﬁrst morning,
pg/mL
12.4 (6.8) 10.6 (2.0) 0.44
Data represent mean (SD) or n (%), unless otherwise indicated.and patientswithout delirium. Thenumbers of patientswithAlzheimer's
disease among those developing delirium and those without delirium
were 1 (11%) and 2 (10%), respectively. There were no signiﬁcant differ-
ences in admission diagnoses between patients developing delirium and
patients without delirium, although stroke, infection, fracture, and heart
failure are risk factors for delirium (Michaud et al., 2007).
A total of 5 of 12 patients admitted to ICUs developed delirium,
whereas 4 of 17 patients admitted to regular acute wards developed
delirium (42% vs. 24%, respectively, relative risk = 1.77, P = 0.42).
3.2. The DRS-R98 severity score at baseline
The mean DRS-R98 severity score of patients developing delirium
was signiﬁcantly higher than that of patients without delirium (7.4
[SD 4.7] vs. 3.6 [4.5], respectively, P = 0.044, Table 1). Therefore, we
assessed the predictive value of the DRS-R98 severity score at baseline
for delirium. Cutoff scores for the DRS-R98 severity score at baseline
were determined using receiver-operator characteristic (ROC) analyses
to determine the Youden Index when comparing patients developing
delirium with patients without delirium.
According to the value of the Youden Index, the best cutoff score for
the DRS-R98 severity score at baseline was 4/5. At the score, sensitivity
of 78%, speciﬁcity 75%, positive predictive value 58%, negative predictive
value 88%, positive likelihood ratio 3.12, and negative likelihood ratio
0.29, indicate that the predictive value of the DRS-R98 severity score
at baseline for delirium is not so high.
3.3. The CDR score at baseline
We examined if CDR score of 0.5 or more, which indicates coexis-
tence of dementia, predicted the development of delirium. The percent-
age of patients developing delirium with a CDR score of 0.5 or more at
baseline was signiﬁcantly higher than that of patients without delirium
(67% vs. 25%, respectively, relative risk, 2.67, P = 0.048). The sensitivity,
speciﬁcity, positive predictive value, negative predictive value, positive
likelihood ratio, and negative likelihood ratio for use of the parameter
for comparison of patients developing delirium with patients without
delirium were 67%, 75%, 55%, 83%, 2.67, and 0.44, respectively.
3.4. Change in blood NK cell activity between the ﬁrst and secondmornings
after admission
There was no signiﬁcant difference between the groups in blood NK
cell activity on theﬁrstmorning after admission (Table 1). However, the
mean change in bloodNK cell activity on the secondmorning, compared
to the ﬁrst morning, in patients developing delirium was signiﬁcantly
greater than that in patients without delirium (6.0% [SD 8.4] vs.−1.4%
[9.0], respectively, t = 2.10, P = 0.045). Signiﬁcant difference between
the groupswas still found after adjusting for age, the history of previous
delirium, and the CDR score, which are well-known risk factors of delir-
ium (Litaker et al., 2001) (F = 6.63, P = 0.017) (Fig. 1). Of note is that 8
of 9 (89%) patients developing delirium had increased blood NK cell
activity, as did only 8 of 20 (40%) patients without delirium, giving
measurement of this parameter, for distinguishing the two groups, a
sensitivity of 89%, speciﬁcity 60%, positive predictive value 50%, negative
predictive value 92%, positive likelihood ratio 2.22, and negative likeli-
hood ratio 0.19.
3.5. Change in blood IL-1β between the ﬁrst and second mornings
after admission
Therewasno signiﬁcant difference between the groups in blood IL-1β
on the ﬁrst morning after admission (Table 1). The signiﬁcant difference
in the mean change in blood IL-1β on the second morning from the ﬁrst














Fig. 1.Change in bloodNK cell activity on the secondmorning compared to the ﬁrstmorn-
ing after admission. The mean change in blood NK cell activity on the second morning
from the ﬁrst morning after admission of patients developing delirium was signiﬁcantly
greater than that of patients without delirium after adjusting for age, the history of previ-
ous delirium, and the Clinical Dementia Rating score (6.0% [SD 8.4] vs.−1.4% [9.0], respec-
tively, F = 6.63, P = 0.017). Cases with the DRS-R98 severity score of 5 or more at
baseline, Cases with the DRS-R98 severity score of 4 or less at baseline.
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[2.2], respectively, t = 1.19, P = 0.24).
3.6. The combination of the DRS-R98 severity score at baseline and the
change in NK cell activity
Of particular note is the fact that the percentage of patients develop-
ing delirium who had both a DRS-R98 severity score of 5 or more at
baseline and an increase in NK cell activity on the secondmorning com-
pared to the ﬁrst morning after admission was signiﬁcantly higher than
that of patientswithout delirium (78% vs. 10%, respectively, relative risk,
7.78, P = 0.0007) (Fig. 1). The sensitivity, speciﬁcity, positive predictive
value, negative predictive value, positive likelihood ratio, and negative
likelihood ratio for use of these two parameters combined for compari-
son of patients developing delirium with patients without delirium
were 78%, 90%, 78%, 90%, 7.80 and 0.24, respectively.
3.7. The combination of the CDR score at baseline and the change in NK
cell activity
The percentage of patients developing deliriumwho had both a CDR
score of 0.5 ormore at baseline and an increase in NK cell activity on the
secondmorning compared to the ﬁrstmorning after admissionwas sig-
niﬁcantly higher than that of patients without delirium (67% vs. 10%, re-
spectively, relative risk, 6.67, P = 0.0039). The sensitivity, speciﬁcity,
positive predictive value, negative predictive value, positive likelihood
ratio, and negative likelihood ratio for use of these two parameters com-
bined for comparison of patients developing delirium with patients
without delirium were 67%, 90%, 75%, 86%, 6.67 and 0.37, respectively.
4. Discussion
4.1. Inﬂammatory response and delirium
An increased inﬂammatory response has been proposed to be
involved in deliriumpathophysiology, as have dysfunction of neurotrans-
mitters, decreased oxidative metabolism, abnormal signal transduction,
changes in blood-brain barrier permeability, and endocrine abnormali-
ties (Cerejeira et al., 2010). In animal studies, there is compelling evi-
dence that acute peripheral inﬂammatory stimulation associated with
functional and molecular changes in the blood–brain barrier (Sparkman
et al., 2006) induces recruitment and inﬁltration of blood-derivedleucocytes into brain tissue (Hofer et al., 2008; Nishioku et al., 2009;
Semmler et al., 2005), activation of brain parenchymal cells, and expres-
sion of proinﬂammatory cytokines and inﬂammatory mediators in the
central nervous system (Cerejeira et al., 2010). However, there is incon-
sistency between ﬁndings in clinical studies about blood levels of cyto-
kines and delirium. One has shown higher blood levels of IL-6 and IL-8
in patients with vs. without post-operative delirium (van Munster
et al., 2008), but another has shown no relationship between blood
IL-6, IL-1β or TNF-α and delirium in elderly medical inpatients (Adamis
et al., 2007). Furthermore, there has been little evidence with respect to
delirium prediction other than IGF-1 (Adamis and Meagher, 2011).
Therefore, the present ﬁnding suggesting the association between in-
creasing blood NK cell activity and risk of delirium may be remarkable.
To our knowledge, there is only one previously reported study
regarding NK cell activity and delirium, which showed no difference in
blood NK cell activity before surgery between 11 patients with postop-
erative delirium and 15 patients without postoperative delirium
(Nakamura et al., 2001). However, blood NK cell activity was measured
only once in that study, so whether NK cell activity was ascending or
descending was not known. In the current study, blood NK cell activity
was measured twice at a 24 h interval, so whether NK cell activity was
ascending or descending was determined for each patient.
Although inﬂammatory blood markers can be abnormal in
Alzheimer's disease (Jadidi-Niaragh et al., 2012), the numbers in the
current study were only 1 (11%) and 2 (10%) among the patients devel-
oping delirium and the patients without delirium, respectively. There-
fore, the effect of their inclusion on the present ﬁndings may have
been small. In addition, inﬂammatory bloodmarkers in Alzheimer's dis-
ease may be more general markers of neurodegeneration without a
strong relationship to the more speciﬁc behavioral and psychological
symptoms of dementia. Such markers may not have affected results of
the 2-time-point observation performed at a 24-h interval in this study.
AsNKcells can be swiftlymobilized bydanger signals and are among
the earliest arrivals at target organs of disease (Shi et al., 2011), a change
in NK cell activity might be suitable as an early indication of an acute
disease such as delirium. In addition, the association between ascending
blood NK cell activity and occurrence of delirium demonstrated in this
study may support an inﬂammatory process as an etiology of delirium,
as NK cells have been shown tomigrate to the inﬂamed central nervous
system (Shi et al., 2011).
Macdonald et al. (2007) reported ﬁrst that high levels of C-reactive
protein (CRP) independently predicted the incidence of delirium, and
that a higher initial Mini-Mental State Examination score and low CRP
predicted the recovery from delirium at any time during hospitalization
for patients with delirium. Since then, attention has been paid to the
association between CRP and delirium. Recently, high baseline inﬂam-
matory biomarkers such as procalcitonin and CRP reportedly predicted
prolonged periods of acute brain dysfunction, implicating inﬂammation
as an important mechanism in the pathophysiology of delirium and
coma in mechanically ventilated patients, irrespective of whether
patients had sepsis (McGrane et al., 2011). These reports suggest a
possible similar mechanism where a general indicator of inﬂammatory
response is associated with delirium.
The present study showed no change in blood IL-1β prior to the
onset of delirium. This is consistent with a previous clinical study that
showed no relationship between blood IL-6, IL-1β or TNF-α and deliri-
um in elderlymedical inpatients (Adamis et al., 2007). Cytokine concen-
tration can vary considerably over time and can be inﬂuenced by an
individual's genetic background, comorbid systemic inﬂammatory
processes, usage of anti-inﬂammatory drugs, and exposure to environ-
mental factors (Flirski and Sobow, 2005). Nevertheless, blood IL-1β
did not change just before developing delirium, in contrast to develop-
ment of agitation as a behavioral and psychological symptom of
Alzheimer disease, as previously reported (Higuchi et al., 2010;
Honma et al., in press). The reason for this difference between delirium
and Alzheimer disease is unclear. An explanation may be that blood
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increasing blood NK cell activity, as delirium is much more acute-onset
than the behavioral and psychological symptoms of dementia (BPSD).
Another explanation may be that the etiology of delirium is associated
with increasing NK cell activity, but not associated with a change in an
inﬂammatory cytokine such as IL-1β, in contrast to BPSD. Third, a
change in blood IL-1βmaynot necessarily reﬂect IL-1β levels in the cen-
tral nervous system.
4.2. Clinical relevance of the change in NK cell activity for deliriumprediction
Monitoring patients at risk of delirium for increasing blood NK cell
activity more closely may have a mild effect, as the positive likelihood
ratio seen in this study was 2.22. In contrast, the negative likelihood
ratio, at 0.19, for the change in NK cell activity ismoderate for a negative
test, and suggests that patients without an increase in NK cell activity
are less likely to develop delirium. However, such patients deﬁnitely
should continue to be monitored regularly, as delirium can actually
develop even in these individuals. With respect to the monitoring of
patients, therefore, a change in NK cell activity may be of only modest
usefulness.
Considering the positive and negative likelihood ratios for compari-
son of patients developing delirium with patients without delirium,
each of two indicators (i.e. the DRS-R98 severity score of 5 or more at
baseline and an increase in NK cell activity on the second morning
from the ﬁrst morning after admission) was a mild positive predictor
and a mild or moderate negative predictor. However, the combination
of these predictors hadmarked synergistic effects, resulting in a positive
likelihood ratio of 7.80 and a negative likelihood ratio of 0.24. These
values suggest that the combination of the two indicators is a moderate
positive predictor of delirium rather than a negative predictor.
With respect to the predictive value for delirium, the CDR score at
baseline was inferior to the DRS-R98 severity score at baseline (positive
likelihood ratio: 2.67 vs. 3.12, respectively; negative likelihood ratio:
0.44 vs. 0.29, respectively). Similarly, the combination of the CDR
score at baseline and the change in NK cell activity was inferior to the
combination of the DRS-R98 severity score at baseline and the change
in NK cell activity (positive likelihood ratio: 6.67 vs. 7.80, respectively;
negative likelihood ratio: 0.37 vs. 0.24, respectively). However, the
difference in the predictive value for delirium between the two param-
eterswas small, and the CDR is simpler than theDRS-R98. Therefore, the
combination of the CDR score at baseline and the change in NK cell
activity might be worth investigating as well as the combination of
the DRS-R98 severity score at baseline and the change in NK cell activity
in future studies.
From the perspective of pharmacological deliriumprevention, a pos-
sibility is raised as the preventive effects of melatonin (Al-Aama et al.,
2011) and its analogue ramelteon (Hatta et al., in press) on delirium
have been demonstrated in placebo controlled randomized trials. Neth-
er melatonin nor ramelteon has serious side effects, so that their use
might not be harmful. Therefore, using melatonin and its analogue
might be justiﬁed for patients having both the DRS-R98 severity score
of 5 or more at baseline and increasing blood NK cell activity, as the
combination of both indicators seems to be a moderate positive predic-
tor. Thus, the present ﬁndings may lead to a pharmacological strategy
for delirium prevention.
4.3. Strength and limitation
One strength of our study was the prospective design. The change in
NK cell activity is predictive and is not the baseline measure, which is
an important difference from other predictor reports. Another strength
was that all participants were emergency cases requiring admission,
mirroring real clinical practice. One limitation was that sample size was
relatively small. It is possible that the number of patients was too small
to detect a sufﬁciently high positive likelihood ratio or a sufﬁciently lownegative likelihood ratio. Further studies including larger numbers of
patients are needed to know if more robust results would be observed.
5. Conclusion
Increased blood NK cell activity is a mild positive predictor of deliri-
um whereas no increased blood NK cell activity is a moderate negative
predictor of delirium. The combination of two predictors, a DRS-R98
severity score of 5 or more at baseline and increased NK cell activity,
is a moderate positive predictor of delirium. Further studies including
larger numbers of patients are needed to justify use of drugs having
preventive effects on delirium and no harmful side effects by patients
having both predictive criteria prior to developing delirium.
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